Lexeo Therapeutics, Inc.
LXEO
$4.84
-$0.12-2.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -28.08% | 3.46% | -3.14% | 22.30% | 20.07% |
| Total Depreciation and Amortization | 1.83% | 1.49% | 1.51% | 3.92% | 1.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 110.50% | 0.44% | -0.37% | 1,051.23% | -107.68% |
| Change in Net Operating Assets | 147.61% | -75.36% | 80.82% | -832.51% | -119.93% |
| Cash from Operations | 16.78% | -5.30% | 32.04% | -8.55% | -25.34% |
| Capital Expenditure | 80.00% | -- | 100.00% | -167.59% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -48.10% | 127.04% | -388.07% | 190.36% | -350.42% |
| Cash from Investing | -48.06% | 127.00% | -390.45% | 189.37% | -351.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -17.36% | 28.40% | -103.61% | 31.97% | 23.27% |
| Issuance of Common Stock | 874.60% | -98.31% | 113,806.67% | -99.83% | 46,958.24% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,016.00% | 99.75% | -- | 100.00% | -- |
| Cash from Financing | 895.07% | -98.29% | 276,384.62% | -99.93% | 663,172.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 140.26% | -60.15% | 298.91% | -16.00% | 207.57% |